TYK MEDICINES-B (02410) gained over 4% in afternoon trading. As of the time of writing, the stock was up 3.87%, trading at HK$14.21, with a turnover of HK$59.4029 million. The movement follows the company's announcement that its self-developed Class 1 new drug, Mesylate Aidotinib Tablets (TY-9591 Tablets), has been proposed by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for inclusion in the priority review list. The intended indication is for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutations, accompanied by central nervous system (CNS) metastases.